Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer
Anderly C. Chüeh(Austin Health), Thomas John(Austin Hospital)
Cited by 16
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386